Table 1 Analytical and operational differences between the screening PCPRO and NGF MRD tests.
From: Utility of flow cytometry screening before MRD testing in multiple myeloma
| Â | PCPRO | NGF MRD |
|---|---|---|
Target event collection | 5 × 105 | 1 × 107 |
Maximum sensitivity | 4 × 10−5 | 2 × 10−6 |
Observed median sensitivity | 4.4 × 10−5 | 2.4 × 10−6 |
Amount of antibody needed | Low | High |
Instrument time per patient | 6 min | 16 min |
Analysis time per patient | 5 min | 20 min |
Gating skills needed | Moderate | High |
PC S-phase assessment | Yes | No |
Hemodilution assessment | No | Yes |
Immune microenvironment assessment | No | Partial |
